ATE391778T1 - Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen - Google Patents

Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Info

Publication number
ATE391778T1
ATE391778T1 AT98904842T AT98904842T ATE391778T1 AT E391778 T1 ATE391778 T1 AT E391778T1 AT 98904842 T AT98904842 T AT 98904842T AT 98904842 T AT98904842 T AT 98904842T AT E391778 T1 ATE391778 T1 AT E391778T1
Authority
AT
Austria
Prior art keywords
vegf
mutants
growth factor
vascular endothelial
endothelial cell
Prior art date
Application number
AT98904842T
Other languages
English (en)
Inventor
Kari Alitalo
Vladimir Joukov
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE391778T1 publication Critical patent/ATE391778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98904842T 1997-02-05 1998-02-02 Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen ATE391778T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/795,430 US6130071A (en) 1997-02-05 1997-02-05 Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof

Publications (1)

Publication Number Publication Date
ATE391778T1 true ATE391778T1 (de) 2008-04-15

Family

ID=25165495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904842T ATE391778T1 (de) 1997-02-05 1998-02-02 Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen

Country Status (7)

Country Link
US (1) US6130071A (de)
EP (1) EP0972028B1 (de)
JP (1) JP4524340B2 (de)
AT (1) ATE391778T1 (de)
AU (1) AU748369C (de)
CA (1) CA2279554C (de)
DE (1) DE69839340T2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
EP0848755B2 (de) * 1995-09-08 2011-02-09 Genentech, Inc. Vegf-verwandtes protein
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (en) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
CA2400948A1 (en) * 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
EP1330252A4 (de) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res In-vivo-stimulierung der angiogenen aktivität
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
DK1385864T3 (da) * 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002256172A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20030232437A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-C expression
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
JP2006517586A (ja) * 2003-02-04 2006-07-27 ラドウィグ インスティテュート フォー キャンサー リサーチ 幹細胞のｖｅｇｆ−ｂ及びｐｄｇｆ調節
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US6990436B1 (en) * 2003-11-28 2006-01-24 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Computing frequency by using generalized zero-crossing applied to intrinsic mode functions
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
EP2085116A1 (de) * 2004-06-30 2009-08-05 University of Rochester Fotodynamische Therapie mit räumlich aufgelöster Dualspektroskopieüberwachung
EP2314614B1 (de) 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogene Verfahren und Zusammensetzungen
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20070282404A1 (en) * 2006-04-10 2007-12-06 University Of Rochester Side-firing linear optic array for interstitial optical therapy and monitoring using compact helical geometry
WO2008080052A1 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Transgenic mice expressing humanized vegf
US20080267924A1 (en) * 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
EP2142254A4 (de) * 2007-05-02 2011-01-26 Univ Rochester Rückmeldungsgesteuertes verfahren zur verabreichung einer fotodynamischen therapie und entsprechendes instrumentarium
US8107710B2 (en) 2008-05-23 2012-01-31 University Of Rochester Automated placental measurement
EP2328480B1 (de) * 2008-07-18 2016-01-06 University Of Rochester Kostengünstiges gerät für fotoakustische c-scan-bildgebung
EP2337500A4 (de) * 2008-10-15 2012-08-29 Univ Rochester Photoakustische bilddarstellung mit einer vielseitigen akustischen linse
WO2010102215A2 (en) * 2009-03-06 2010-09-10 University Of Rochester Automated placental measurement
US20110081056A1 (en) * 2009-10-05 2011-04-07 Salafia Carolyn M Automated placental measurement
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
WO2021186024A1 (en) * 2020-03-20 2021-09-23 Centre National De La Recherche Scientifique (Cnrs) New anti-vegfc antibodies and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
DE69034135T3 (de) * 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
EP0506477B1 (de) * 1991-03-28 1999-06-23 Merck & Co. Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) * 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JPH09510093A (ja) * 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
NZ288235A (en) * 1994-06-09 1999-05-28 Orion Corp Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3
EP0848755B2 (de) * 1995-09-08 2011-02-09 Genentech, Inc. Vegf-verwandtes protein
WO1997017442A1 (en) * 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein

Also Published As

Publication number Publication date
DE69839340D1 (de) 2008-05-21
AU748369B2 (en) 2002-06-06
JP2001523951A (ja) 2001-11-27
JP4524340B2 (ja) 2010-08-18
AU748369C (en) 2003-03-20
AU6262498A (en) 1998-08-25
CA2279554A1 (en) 1998-08-06
US6130071A (en) 2000-10-10
CA2279554C (en) 2012-09-18
EP0972028A1 (de) 2000-01-19
DE69839340T2 (de) 2009-04-09
EP0972028B1 (de) 2008-04-09

Similar Documents

Publication Publication Date Title
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
ATE306546T1 (de) Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
ATE352618T1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
BG112042A (bg) Човешки антитела, свързващи човешки тумор некрос фактор- ? (tnf-?)
DK0914345T3 (da) Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
NO973933D0 (no) Vaskulær endotelvekstfaktor B
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
NO930011L (no) Tilfeldig boi-oligomer bibilotek og fremgangsmaate for syntese og anvendelse derav
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
MXPA02008239A (es) Gen humano de la esquizofrenia.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
NZ504025A (en) Vitamin D receptor related polypeptides (VDRR) and its use in treating inflammatory disease
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
DE69734596D1 (de) "smoothened" proteine aus wirbeltieren
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
AR010333A1 (es) Una muteina ob, una secuencia de adn, un vector de expresion una celula hospedadora procariota o de mamifero, un baculovirus recombinante, una celulahospedadora, un metodo para la produccion de una muteina ob, una composicion farmaceutica, el uso de una proteina ob para la preparacion de una composi
ATE103979T1 (de) Menschliches lymphotoxin.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties